Friday, November 20, 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 499: (TSX: $DN.TO) (NASDAQ: $VFF) (TSX: $VFF.TO) (CSE: $CURA.C)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 499: (TSX: $DN.TO) (NASDAQ: $VFF) (TSX: $VFF.TO) (CSE: $CURA.C)
Delta, Kelowna, BC, November 20, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/112020-StocksToWatch.mp3
Read this in full at
https://www.investorideas.com/news/2020/cannabis-potcasts/11201DN-VFF-CURA.asp
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we will be looking at a few private and public company announcements.
DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) announced that it has completed its final services milestone under an agreement with Ahahswinis Green Investments Ltd (“Ahahswinis”) which is 100% owned by Hupacasath First Nation. Ahahswinis is an arms length third party in which Delta 9 has no ownership control or interest.
As one of Delta 9’s micro cultivation partners, Ahahswinis entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, and other services supporting the acquisition of the Health Canada license. On November 13, 2020, Ahahswinis confirmed it has reached its final milestone under the SCA and has been granted a cannabis micro cultivation license from Health Canada (the “Health Canada License”).
“We are pleased with having achieved this major milestone in our agreement with Ahahswinis and thrilled that they are the first Delta 9 micro cultivators in Canada to be 100% wholly owned by a First Nation and receive a Health Canada Licence for our proprietary and turn-key 'Grow Pod' systems”, said John Arbuthnot, Founder and CEO of Delta 9. “We are continuing to work with First Nations in Canada to develop our micro cultivation services so that our platform can be the "go to" platform for cannabis entrepreneurs looking to produce premium quality cannabis products.”
The Company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are retrofitted standard 40-foot shipping containers. Ahahswinis’s facility has been designed and built using this turn key and state of the art Grow Pod system. Once cultivation begins, Delta 9 plans to purchase premium quality cannabis products from Ahahswinis for distribution through the Company's established distribution network, and through Delta 9's branded retail stores.
“I would like to thank Delta 9 for providing us with a turn-key platform to grow cannabis and for their continued support as we begin production in December 2020", said James Tatoosh, President. "Their proven grow pod design made it easier to receive a Health Canada license and apply and receive funding from the Nuu Chah Nulth Economic Development Corp. (NEDC). We look forward to being a part of this new industry producing small batch, premium grown, craft cannabis.”
The Hupacasath First Nation has owned and occupied their traditional territory in Central Vancouver Island for thousands of years. Their goal is to enhance the quality of life for their people by providing jobs and economic development opportunities so families can support themselves. They have invested $1.9 million in the 4,560 square foot micro cultivation operation with 12 Delta 9 Grow Pods, located outside of Port Alberni Vancouver Island, British Columbia.
Pure Sunfarms, the wholly owned subsidiary of Village Farms International Inc. (NASDAQ: VFF) (TSX: VFF), announced that their brand will be appearing as part of a limited-edition Lane Crawford x Found CBD-infused gift set to be sold in the luxury department store’s holiday pop-up shops in Hong Kong. This is Pure Sunfarms first international appearance as a leading Canadian cannabis brand.
Pure Sunfarms’ brand’s appearance on the international stage stems as a result of a partnership between Altum International Limited’s Found, Asia-Pacific’s first CBD retail platform and café, and Lane Crawford, an iconic luxury department store in Greater China. The co-branded holiday pop-up shops aim to educate consumers and elevate their awareness about CBD.
Luxury gift sets available for purchase at the pop-up shops will feature Pure Sunfarms’ CBD gummies created specifically for the Hong Kong consumer, among other CBD-inspired items such as chocolates, bath salts, and tea bags.
“We’re so pleased for the Pure Sunfarms’ brand to make its debut internationally, alongside such prestigious and progressive partners as Altum and Lane Crawford,” said Mandesh Dosanjh, President & CEO, Pure Sunfarms. “This is just the beginning of what’s to come for Pure Sunfarms as we look to share our love our plants and B.C.-grown cannabis products with the global cannabis market.”
“We are particularly excited to be able to present in Asia-Pacific for the first time, Pure Sunfarms, Canada’s market leading cannabis brand,” Fiachra Mullen, Chief Marketing Officer for Altum International. “We believe that the leading cannabis brands in the Canadian market will hold a special place in the Hong Kong consumer’s heart. We are incredibly proud to have their trust in helping them access the Asia-Pacific markets for the first time through the most progressive cannabinoid jurisdiction in the region - Hong Kong.”
The pop-up shops will run from November 13 through to the end of December 2020 at Lane Crawford’s ifc mall, Canton Road and Times Square locations.
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading U.S. provider of consumer products in cannabis, announced today the launch of its NANO Chews product in the Florida market. Curaleaf's sugar-free, fast-acting NANO Chews offer a reliable and consistent cannabis experience and are available at Curaleaf's retail locations across the state, including the two newest dispensaries which recently opened in Pensacola and Panama City.
Utilizing nano-emulsion technology, Curaleaf NANO Chews are ideal for patients seeking a faster onset time and more calibrated experience. With 5mg of THC per piece, NANO Chews are infused with small, water-soluble cannabinoids. This technology allows patients to feel the product's full effects in roughly half of the time of a traditional edible. NANO Chews are typically preferred among patients who are looking for quicker relief than traditional edibles offer. Curaleaf NANO Chews are available in the sugar-free flavor of Arctic Berry at launch, with additional flavors to follow, and Classic Chews, a more traditional edible, are also expected to launch in Florida in the coming weeks. Per Florida state regulations, the product does not contain any natural or artificial color additives.
Florida's Department of Health officially authorized medical applications of edibles in September. Prior to the announcement, Curaleaf released a selection of premium products in Florida, including first-to-market Sublingual Tablets, Select Elite Live cartridges, and RSO. Since then, the Company has debuted both NANO Drops and Live Blends in Florida, all of which cater to a variety of patient preferences.
"We're thrilled to bring NANO Chews to Florida," said Joe Bayern, President of Curaleaf. "This is the next step in delivering true innovation to the market. After receiving incredible feedback from patients in states where NANO Chews have already launched, we are confident that Floridians who've waited nearly four years for edibles will embrace a new kind of cannabis experience with NANO Chews."
Florida is an increasingly fast-growing medical marijuana market in the United States with over 430,000 registered medical patients. Curaleaf currently operates 33 dispensaries in Florida and 95 dispensaries nationwide. To see Curaleaf's dispensary locations in Florida, along with hours of operation and contact information, please visit www.curaleaf.com/locations/#florida.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Thursday, November 19, 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 498: (TSX: $CWEB.TO) (TSXV: $PCLO.V) (TSXV: $BEER.C) (CSE: $LXX.C)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 498: (TSX: $CWEB.TO) (TSXV: $PCLO.V) (TSXV: $BEER.C) (CSE: $LXX.C)
Delta, Kelowna, BC, November 19, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/111920-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/11191CWEB-PCLO-BEER-LXX.asp
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we will be looking at a few private and public company announcements.
Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX:CWBHF), the market leader in hemp CBD extract products, announced a collaboration between its CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program that provides a better understanding of the therapeutic uses and safety of cannabinoids.
This new scientific initiative builds on early projects that have been envisioned with Dr. Gene D. Morse, Director of the Center for Integrated Global Biomedical Sciences (CIGBS) at the University at Buffalo and State University of New York (SUNY) Distinguished Professor. The new partnership includes collaboration on a global program to advance cannabinoid sciences implementation research and safety for both supplement and biomedical use of cannabinoids with the coordination center at Buffalo, N.Y. Its purpose is to identify optimal approaches to advance the safe use of cannabinoid-containing products and identify the gaps in current knowledge. The program will include the design and implementation of novel population-based clinical informatics analysis using large databases, pilot projects that facilitate better understanding of pre-clinical and clinical pharmacology, and drug interactions to develop safe approaches to cannabinoid therapy.
"Charlotte's Web's CW Labs has an advanced team of scientists based here on the medical campus. We are excited to work with the clear leaders in the hemp sector, both in the quality of their hemp genetics and their products," said Dr. Morse.
"We realize the value of partnering our established cannabinoid product business models with an internationally recognized leader in clinical research to address the growing field of cannabinoid health and wellness products," said Tim Orr, CW Labs' Senior Vice President of Innovation. "This collaboration will oversee multidisciplinary teams conducting cutting edge research in new areas of implementation to expand the database of evidence that can guide future therapeutics development in the field. We are pleased to have established this working relationship with UB's Center for Integrated Global Biomedical Sciences and the opportunity that this new alliance creates."
Building of this multi-disciplinary team is underway. It includes UB investigators: Dr. Laszlo Mechtler, a Neurologist and Neuro-oncologist in the department of Neurology, Medical Director of the Dent Neurologic Institute and it's Cannabis Clinic and Research Center, as well as the Chief of Neuro-Oncology at Roswell Park Comprehensive Cancer Center, Dr. Jason Sprowl, a pharmaceutical scientist in the department of Pharmaceutical Sciences at UB, investigators at the University of the West Indies, Mona Campus, Jamaica, Dr. Marvin Reid, director of the Tropical Medicine Research Institute, Professor Thejani Delgoda, who leads the Natural Products Institute, and Professor Wendel Abel of Community Health and Psychiatry. At the University of Zimbabwe, Professor Charles Maponga, Director of the Clinical Pharmacology Laboratory, is engaged with planning clinical research and related regulatory policies to promote safe cannabinoid use.
The collaboration will pursue implementation research related to the wellness aspects of cannabinoids through the established national and global capacity-building efforts that form the foundation of the UB Center for Integrated Global Biomedical Sciences. This includes programs that have been developed with the Dent Neurologic Institute, home to one of the nation's largest and most comprehensive physician-directed medical cannabis programs with more than 15,000 active patients, the University of the West Indies, Mona Campus in Jamaica, and the University of Zimbabwe Center of Excellence in Pharmaceutical Innovation in the developing Health Galaxy Park site in Harare, Zimbabwe. The goal is to build a global collaboration of partners with an interest in cannabinoid sciences that includes pre-clinical and translational pharmacology, human safety, and community-based health informatics.
"These scientists bring global expertise in areas such as cellular transport mechanisms that influence cannabinoid distribution throughout the body, clinical pharmacology mechanisms that contribute to different responses among individuals and potential interactions between botanical cannabinoids and commonly used medications and will contribute to a global understanding of cannabinoids" said Dr. Morse.
Dr. Morse, and Dr. Jeffrey C. Lombardo, Program Coordinator for Global Cannabinoid Sciences, will lead the collaboration with CW Labs. Dr. Morse, Director of the Translational Pharmacology Research Core and co-Director of the Drug Development Center at UB, has extensive experience with pharmacologic assay development, designing, implementing and analyzing clinical trials with pharmacokinetics and pharmacodynamics. The collaboration with CW Labs Inc. will create a novel partnership with the Global Cannabinoids Research program at the Center for Integrated Global Biomedical Sciences.
PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) and MINO Labs S.A. de C.V., the founders of PharmaCielo S.A. de C.V., congratulate Mexican Senate members for advancing the much-needed cannabis legislation and subsequent reform by voting to move forward the legalization bill, which includes provision for import of medicinal extracts and products.
David Attard, CEO of PharmaCielo Ltd., says, "The recent vote is an important development and positive momentum toward bringing cannabis reform to the finish line by the mid-December deadline. The partnership we established with MINO Labs last year as PharmaCielo Mexico is a precursor to what we expect will become an important and vibrant market for cannabis-derived health and wellness products, for which we aim to become a primary supplier of high-quality medicinal-grade oils and isolates."
Manuel Cosme Odabachian, CEO of MINO Labs, stated, "Mexican lawmakers made it loud and clear today that adult cannabis usage should be legalized. The Senators' votes in favor of the new bill are a huge step forward and a development welcomed by both end-users and industry participants. For the past 20 years, MINO Labs has been a leading specialty supplier and distributor of pharma-grade products in Mexico. Together with PharmaCielo we have built a great infrastructure to provide the Mexican market with top-notch cannabis extract product offerings – and we are ready to deliver!"
PharmaCielo and MINO Labs founded PharmaCielo Mexico last year as a joint venture. The purpose of the joint venture is to bring PharmaCielo's high-quality cannabis extracts and derivative products from its Colombian cultivation and processing centre to the Mexican market by leveraging MINO Labs' extensive experience and broad presence in the country's pharma distribution space. Upon completion of the legislative process, PharmaCielo Mexico will commence the sale and distribution of medicinal cannabis products, including those for wellness and lifestyle segments, in Mexico.
Distribution of cannabis products by PharmaCielo in Mexico will be subject to the approval of the TSX Venture Exchange (the "TSXV").
Hill Street Beverage Company Inc. (TSXV: BEER) announced that it has signed a definitive agreement to acquire the primary assets of Lexaria Canpharm, the cannabis-related division of Lexaria Bioscience Inc. (CSE: LXX). This acquisition provides Hill Street with the exclusive rights in perpetuity to use Lexaria's ground-breaking DehydraTECHTM patent portfolio on a global basis to make any type of products containing THC and other psychoactive cannabinoids. In addition, the agreement expands Hill Street's license with Lexaria HempCo to make products containing CBD on a global basis for ten years.
Terms of the acquisition
● Total consideration of $3.85 million, including $350K in cash upon closing and future payments of $2.0 million.
● Hill Street will issue Lexaria Bioscience a total of $1.5MM worth of Common Shares in the capital of the Company in three equal installments with the first tranche issuable on closing. The first tranche will be issued at a price of $0.0829 per share, which is equal to the 10-day volume weighted average closing price of the Common Shares on the TSX Venture Exchange on the date hereof. All successive issuances shall be issued at the greater of (A) the 10-day volume weighted average closing price of the Common Shares on the TSX Venture Exchange on such payment date; and (B) $0.0829;
With over sixty patents for DehydraTECHTM either issued or pending, this transaction positions Hill Street to expand its strategy of producing ingredients for Cannabis 2.0 products, allowing the Company to take advantage of growing demand for "quick onset and duration" recreational cannabis edibles and topicals. This transaction will allow Hill Street to expand its addressable market to every country in the world where cannabis is either medicinally or recreationally legal. Lexaria's Intellectual Property converts perishable cannabis products such as oils and extracts into shelf stable powders. Hill Street will manufacture these powders for sale to licensed cannabis processors at its own facility as well as sub-license the technology to licensed manufacturers globally. Shelf stable cannabis powders are the ideal ingredients upon which to build world class Cannabis 2.0 brands, including beverages, edibles, and topicals. The DehydraTECHTM processes are well researched, market validated, and well protected through multiple patents, and will continue to improve as Lexaria continues its research.
Completion of the transaction is subject to the approval of the TSX Venture Exchange.
"With this transaction, we are building on an already strong partnership with Lexaria. We are gaining full ownership of the joint manufacturing partnership we created last year, and positioning Hill Street to become an early leader in the global market for cannabis 2.0 ingredients and products. Our cannabis processing facility is designed specifically to produce shelf stable ingredients using DehydraTECHTM for the Cannabis 2.0 market," said Terry Donnelly, Chairman & CEO of Hill Street. "With a significant portion of the consideration in shares and future payments, this transaction demonstrates Lexaria's faith in Hill Street to unlock the value of their innovations for their shareholders based on our success."
"Hill Street's team is executing a new and exciting strategy in the cannabis sector, designed to take advantage of the Cannabis 2.0 market and enhanced consumer expectations," stated Chris Bunka, Chairman & CEO of Lexaria Bioscience. "Their deep expertise in consumer goods will allow consumers to experience Lexaria's innovations through the highest performance products available in the Cannabis 2.0 sector. Lexaria's focus remains on creating the greatest innovations possible in drug delivery in the diverse sectors of nicotine, cannabinoids, and antivirals for both the therapeutic and pharmaceutical industries. Innovations in drug delivery in the pharmaceutical industry represents a massive global opportunity for Lexaria, and this transaction with Hill Street assists our ability to focus, while providing our shareholders with a significant carried interest in a fast growing startup well positioned for success in the cannabis 2.0 market."
Canndora, the global media and event platform, and initiative created by Marigold Marketing & PR to support advancing women in emerging industries has announced it is hosting #CanndoraConnect: Women in Psychedelics event.
A virtual event, #CanndoraConnect: Women in Psychedelics is open to audiences worldwide and will take place 2:00-4:00 p.m. EST on Wednesday, December 2nd, 2020. The event will offer attendees a unique experience, providing collaboration, networking, inspiration, and advice for women's success in the emerging psychedelics industry worldwide.
“We are honoured to be partnering with Canndora to create a movement that is bringing awareness and attention to advancing women in the emerging psychedelics industry,” says Todd Shapiro, CEO & Director of Red Light Holland. “This is an exciting event that will provide amazing opportunities to network, learn, connect and feel inspired by all of the extraordinarily intelligent speakers and panellists, including Ann Barnes and Sarah Hashkes, whom we are proud and grateful to work so closely with at Red Light Holland.”
Attendees will hear from influential speakers, learn best industry practices for success, and network with leading industry experts in psychedelics. The event will feature notable industry professionals and panelists who will share their expertise on critical topics, including opportunities for international business in psychedelics and the science behind psilocybin and its role in women's health.
Industry leaders and speakers in attendance include:
● Ann Barnes, Director of Red Light Holland
● Sarah Hashkes, CEO of Radix Motion
● Terri Smith, Chief Mycologist of WAKE
● Dr. Olga Chernoloz, Chief Scientific Officer of WAKE
● Susan Chapelle, President of Havn Life
● Irie Selkirk, Co-founder & Director of Rise Wellness Retreats
“2020 is the year the voice of psychedelic renaissance has been heard the loudest,” says Dr. Olga Chernoloz, Chief Scientific Officer of WAKE. “So far the data streaming from the psychedelic clinical studies has been exceptionally promising. It gives hope to the development and recognition of new treatment modalities for the support of mental health. Women, often disproportionately affected by these conditions, could find a way to re-process the underlying emotional content and find balance with help of the psychedelic-assisted therapy.”
Now hosting its seventh professional event for emerging industries, including sell-out attendance in previous cannabis women-focused events, the #CanndoraConnect: Women and Psychedelics event is positioned to be a hailed success. The event is made possible with support from presenting partners, Red Light Holland (CSE: TRIP) (OTC: TRUFF) and WAKE.
The #CanndoraConnect: Women in Psychedelics event is open to anyone 19+. Tickets are CAD$15.00 and attendees are encouraged to register as soon as possible as spaces are limited. To purchase tickets, register on Eventbrite.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Wednesday, November 18, 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 497 (NASDAQ: $SAMA), (CSE: $DELC.C), (TSXV: $PCLO.V), (TSXV: $N.V)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 497 (NASDAQ: $SAMA), (CSE: $DELC.C), (TSXV: $PCLO.V), (TSXV: $N.V)
Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland
Delta, Kelowna, BC, November 18, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/111820-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/11181SAMA-DELC-PCLO-N.asp
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
In today’s podcast we will be looking at a few private and public company announcements.
Clever Leaves International Inc., a leading multi-national operator and licensed producer of pharmaceutical-grade cannabinoids, provided an update on their current international footprint by announcing successful exportation of cannabis products to 14 different countries and 5 continents as of Q4 of 2020. The products range from raw materials, including active pharmaceutical ingredients (APIs) and semi-finished products, including white label products.
Clever Leaves’ international network highlights the Company’s ability maintain important partnerships with regulatory agencies and governments as well as the ability to navigate pandemic-related supply chain setbacks. In compliance with all cannabis regulations in the countries served, the Company’s portfolio of products has been exported to Australia, Brazil, Canada, Chile, the Czech Republic, Germany, Israel, Netherlands, Perú, Poland, Spain, South Africa, the United Kingdom, and the United States.
“Most of the international cannabis industry functions like a pharmaceutical channel requiring significant investments of time and focus by both a supplier such as Clever Leaves and its commercial partners throughout the world. Success depends on navigating nascent but strict regulatory systems, and relationships often require initial small batch or sample shipments and validation before larger partnerships can emerge. COVID-19 has introduced new challenges even when it comes to basic transportation logistics. These milestones across our export network strengthen our ability to deliver value to our business partners and to patients around the world,” said Kyle Detwiler, CEO of Clever Leaves.
“The resilience, professionalism, and creativity in times of setback, have been critical to the success of our team to navigate complex regulatory frameworks and to meet customers' deadlines during a time of unparalleled logistical restrictions. Additionally, we are grateful to work in partnership with local regulatory agencies and logistics service providers who share the same goal to bring high-quality medical cannabis products to patients and are committed to the advancement of the global cannabis market,” said Andrés Fajardo, President of Clever Leaves.
The Company was granted their EU GMP certification for cannabis extracts in July 2020, establishing Clever Leaves’ facilities in Colombia as the first and only operation to be granted EU GMP certification in Latin America and one of a select few in the world. The certification, which is generally required to import medical cannabis products into the European Union, allows Clever Leaves to produce API, semi-finished and finished products to be distributed in pharmaceutical channels. Additionally, in August 2020, Clever Leaves was granted a provisional license in Portugal from Infarmed, the Portuguese health authority that allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes.
Clever Leaves recently announced that it amended its definitive agreement with Schultze Special Purpose Acquisition Corp. (NASDAQ: SAMA), pursuant to which a newly formed holding company, Clever Leaves Holdings Inc. will acquire SAMA and Clever Leaves. The transaction is expected to close in the fourth quarter of 2020, with Holdco anticipated to become a Nasdaq-listed public company trading under the ticker symbol “CLVR".
Delic Holdings Inc., a psychedelic-focused media, e-commerce and event company, announced that effective at market open today, the Company will begin trading on the Canadian Securities Exchange under the ticker symbol (CSE: DELC).
Jackee Stang, CEO of DELIC comments “Canada has consistently shown leadership in helping cannabis and now psychedelics emerge from false stigmas. Canada was the first G7 country to legalize cannabis, and as psychedelics further gain ground on what may appear as false stigmas, the health and wellness sector will only grow. As such, the DELIC community is deeply proud to be a part of the Canadian Securities Exchange. We started DELIC to mainstream the psychedelic conversation, advocate for cognitive freedom and ultimately see an end to the War on Drugs.”
Ms. Stang continued, “As the first ever psychedelic wellness corporation, it is our mission to open the doors of psychedelic healing to the masses. We decided to take DELIC public because we believe that psychedelic wellness should be open to everyone... All people from diverse backgrounds and varied life experiences. DELIC is the first ever psychedelic wellness company designed to disrupt the status quo by diversifying our operations, maintaining sensible messaging and intentionally avoiding dogmatic practices or binary rhetoric. We believe in being pragmatic and maintaining a clear-headed approach as the psychedelic sector continues to build.”
In conjunction with the previously-announced business combination with Molystar Resources Inc., DELIC raised $3,475,500 through a non-brokered private placement offering.
On November 17, 2020, the Company issued an aggregate of 3,450,000 options to directors, officers and certain advisors pursuant to the Company’s share compensation plan — each with an exercise price of $0.25, vesting as to 1/3 of such options on each of the 6, 12 and 18-month anniversaries, and expiring in three years.
PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced that it has delivered its first commercial shipment of medicinal grade CBD isolate to a well-established, bulk distributor and white label manufacturer based in the U.K., with sales and distribution operations in the U.K., and the E.U.
In addition, the Company has reached an interim sales agreement with the Customer, lasting until the end of Q1-2021, at which point PharmaCielo expects to have submitted a Novel Foods authorization application for its range of CBD extracts. The interim, renewable agreement enables continued shipments for the remainder of 2020 and calls for the shipment of up to 1,000 kg of CBD Isolate and Broad-Spectrum CBD based on the Customer's specifications, during Q1-2021. With submission of the Novel Foods authorization application prior to March 31, the Company expects to be in a position to subsequently expand both volume and exported consumable product types during fiscal 2021 in accordance with regulatory requirements.
"As consumer demand for health and wellness products containing cannabinoids continues to expand, PharmaCielo is well-positioned to deliver a portfolio of medicinal-grade extracts at scale to serve the needs of global CBD-market facing providers," said David Attard, CEO of PharmaCielo Ltd. "Having focused to date on building a world-class infrastructure in Colombia as well as developing a robust product portfolio, we are ideally positioned to become the supplier of choice for large volume B2B sales globally. 2021 will be a very exciting year for the Company as we significantly expand global export volumes, and the addition of the Customer's relationships throughout international markets long-term, including the U.K. and E.U., support this focus."
Distribution of CBD products by the Company under its interim sales agreement with the Customer is subject to the approval of the TSX Venture Exchange (the "TSXV").
Namaste Technologies Inc. (TSXV: N) (OTC: NXTTF), a leading platform for cannabis products, accessories, and education, announced that it has entered into a share purchase agreement to acquire the remaining 49% interest in CannMart Labs Inc., an applicant for a processing licence under the Cannabis Act (Canada) for cannabis extraction activities.
Transaction Highlights:
● Namaste to acquire remaining 49% of CannMart Labs to 100% ownership
● CannMart Labs facility in Ontario is completed for BHO extraction using leading extraction technology, making it one of only a few facilities in Canada with such capabilities
● Application in final phase for a processing licence from Health Canada
● Set to produce in-house branded Cannabis 2.0 products for medical channel customers at CannMart.com and recreational customers across Canada through sister company CannMart Inc.'s network of provincial sales partners
● Cannabis 2.0 products initially planned include shatter and live resin with capabilities to expand future distillate product offerings to vape cartridges, gel capsules, tinctures and edibles
In May 2018, Namaste acquired a 51% interest in CannMart Labs and agreed to finance the construction of its facility in Etobicoke, Ontario, a purpose-built oil extraction facility which incorporates a leading extraction technology facility designed to meet EU Good Manufacturing Practice (EU-GMP) certification requirements.
"Acquiring the remaining interest in CannMart Labs is another important milestone achieved in establishing Namaste as a leading company within the Canadian cannabis sector," said Meni Morim, Chief Executive Officer of Namaste. "CannMart Labs is in the final stage of its application for an important processing licence from Health Canada. It has installed state-of-the-art extraction technology in its facility, which when granted a licence, will be able to produce an array of cannabis products including shatter and live resin, as well as future distillate products such as vape cartridges, gel capsules, tinctures and edibles."
Mr Morim added: "This transaction is advantageous to Namaste shareholders as the Vendors will continue to provide management services and will receive earn-out payments in the form of Namaste common shares or cash only upon the successful achievement of certain revenue and gross profit targets and if the targets are met, the cash payment option allows Namaste to minimize dilution associated with the acquisition. We are working hard towards receiving our processing licence from Health Canada and look forward to producing in house branded Cannabis 2.0 products, for our medical channel customers at CannMart.com and recreational consumers across Canada through our network of provincial sales partners."
Under the terms of the proposed transaction (the "Proposed Transaction"), Namaste will acquire the remaining 49% interest of CannMart Labs from MKD Holdings Inc. and JLLS Holdings Inc. in exchange for a purchase price of $4,034,000. A first tranche of the Purchase Price of $1,608,500 will be paid to the Vendors in common shares of Namaste issued at a deemed price equal to the seven day volume weighted average price of Namaste's common shares on the TSX Venture Exchange (the "VWAP") on the closing date of the Proposed Transaction. The remaining Purchase Price of $2,425,500 is payable to the Vendors in equal tranches over the next nine fiscal quarters beginning on the fiscal quarter ending February 28, 2021, at the VWAP on the date of issuance required within 5 days of the end of the applicable fiscal quarter.
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Subscribe to:
Posts (Atom)